News
CLPBY
7.49
+2.74%
0.20
Coloplast: Turnaround Is Underway, But Upside Is Limited
Seeking Alpha · 5d ago
Weekly Report: what happened at CLPBY last week (1102-1106)?
Weekly Report · 11/09 09:24
Coloplast Sees Revenue for 2027 FY is expected to be up by 7% to 9% YoY
Benzinga · 11/03 08:45
Coloplast Q4 Adj. EPS $0.09, Inline, Sales $1.148B Beat $1.120B Estimate
Benzinga · 11/03 07:12
Weekly Report: what happened at CLPBY last week (1026-1030)?
Weekly Report · 11/02 09:24
Weekly Report: what happened at CLPBY last week (1019-1023)?
Weekly Report · 10/26 09:23
Weekly Report: what happened at CLPBY last week (1012-1016)?
Weekly Report · 10/19 09:24
Weekly Report: what happened at CLPBY last week (1005-1009)?
Weekly Report · 10/12 09:25
Weekly Report: what happened at CLPBY last week (0928-1002)?
Weekly Report · 10/05 09:25
Weekly Report: what happened at CLPBY last week (0921-0925)?
Weekly Report · 09/28 09:24
Weekly Report: what happened at CLPBY last week (0914-0918)?
Weekly Report · 09/21 09:24
Weekly Report: what happened at CLPBY last week (0907-0911)?
Weekly Report · 09/14 09:25
Weekly Report: what happened at CLPBY last week (0831-0904)?
Weekly Report · 09/07 09:23
Weekly Report: what happened at CLPBY last week (0824-0828)?
Weekly Report · 08/31 09:25
Coloplast: Great Business, Fair Price, Bad Timing
Seeking Alpha · 08/28 07:06
Weekly Report: what happened at CLPBY last week (0817-0821)?
Weekly Report · 08/24 09:26
Coloplast A/S Non-GAAP EPS of DKK 6.55, revenue of DKK 7.26B; reaffirms FY 2026 outlook
Seeking Alpha · 08/19 05:08
Full Transcript: Coloplast Q3 2026 Earnings Call
Benzinga · 08/18 10:17
Coloplast Affirms FY2026 Sales Guidance of $4.499B vs $4.420B Est
Benzinga · 08/18 09:19
Coloplast Q3 Adj. EPS $0.10, Inline, Sales $1.144B Beat $1.120B Estimate
Benzinga · 08/18 09:04
More
Webull provides a variety of real-time CLPBY stock news. You can receive the latest news about Coloplast As Drc through multiple platforms. This information may help you make smarter investment decisions.
About CLPBY
Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.